Last reviewed · How we verify
Heparin Sodium In Plastic Container (Heparin Sodium)
Heparin Sodium In Plastic Container (generic name: Heparin Sodium) is a Anti-coagulant Oligosaccharide drug developed by Fresenius Kabi. It is currently FDA-approved (first approved 1939) for Deep Vein Thrombosis with Pulmonary Embolism, Deep venous thrombosis, Disseminated intravascular coagulation.
Heparin enhances Antithrombin III's activity to inhibit coagulation factors Xa and IIa, preventing clot formation.
Heparin Sodium is an anti-coagulant medication originally developed by Organon USA Inc and currently owned by Fresenius Kabi USA. It targets Antithrombin-III and is used to treat various conditions such as deep vein thrombosis, pulmonary embolism, and non-Q wave myocardial infarction. Heparin Sodium is a small molecule medication that has been FDA approved since 1939 and is now off-patent with 19 generic manufacturers. It is used to prevent blood clot formation and maintain patency of indwelling vascular catheters. Key safety considerations include monitoring for bleeding and thrombocytopenia.
At a glance
| Generic name | Heparin Sodium |
|---|---|
| Sponsor | Fresenius Kabi |
| Drug class | Anti-coagulant |
| Target | Antithrombin III, Factor Xa, Factor IIa |
| Modality | Oligosaccharide |
| Phase | FDA-approved |
| First approval | 1939 |
Mechanism of action
Heparin works by interacting with Antithrombin III, a natural protein in the blood. This interaction changes the shape of Antithrombin III, making it more effective at blocking the enzymes that cause blood to clot, specifically Factor Xa and thrombin (Factor IIa). By doing so, heparin prevents the formation of clots but does not dissolve existing ones.
Approved indications
- Deep Vein Thrombosis with Pulmonary Embolism
- Deep venous thrombosis
- Disseminated intravascular coagulation
- Maintain Patency of Indwelling Vascular Catheter
- Non-Q wave myocardial infarction
- Peripheral Arterial Thromboembolism Prevention
- Peripheral arterial embolism
- Prevention of Cardiac Ischemia in Unstable Angina
- Prevention of Ischemic Complications of Non-Q Wave MI
- Prevention of Recurrent Venous Thrombosis Associated with Malignancy
- Prevention of deep vein thrombosis
- Pulmonary Thromboembolism Prevention
- Pulmonary thromboembolism
Common side effects
- Heparin-induced thrombocytopenia
- Vascular stent thrombosis
- Haemorrhage
- Haematoma
- Labelled drug-drug interaction medication error
- Premature baby
- Cardiogenic shock
- Multiple organ dysfunction syndrome
- Shock haemorrhagic
- Premature delivery
- Arthralgia
Drug interactions
- magnesium salicylate
- salicylic acid
- salsalate
- thiosalicylic acid
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery (PHASE1)
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Zeus (510K) - 24024 - Stability in Venous and Arterial Blood
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Heparin for RAO Post-Transradial Angiography in AIS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin Sodium In Plastic Container CI brief — competitive landscape report
- Heparin Sodium In Plastic Container updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI
Frequently asked questions about Heparin Sodium In Plastic Container
What is Heparin Sodium In Plastic Container?
How does Heparin Sodium In Plastic Container work?
What is Heparin Sodium In Plastic Container used for?
Who makes Heparin Sodium In Plastic Container?
What is the generic name of Heparin Sodium In Plastic Container?
What drug class is Heparin Sodium In Plastic Container in?
When was Heparin Sodium In Plastic Container approved?
What development phase is Heparin Sodium In Plastic Container in?
What are the side effects of Heparin Sodium In Plastic Container?
What does Heparin Sodium In Plastic Container target?
Related
- Drug class: All Anti-coagulant drugs
- Target: All drugs targeting Antithrombin III, Factor Xa, Factor IIa
- Manufacturer: Fresenius Kabi — full pipeline
- Indication: Drugs for Deep Vein Thrombosis with Pulmonary Embolism
- Indication: Drugs for Deep venous thrombosis
- Indication: Drugs for Disseminated intravascular coagulation
- Compare: Heparin Sodium In Plastic Container vs similar drugs
- Pricing: Heparin Sodium In Plastic Container cost, discount & access